ritonavir has been researched along with Lymphoma* in 2 studies
2 other study(ies) available for ritonavir and Lymphoma
| Article | Year |
|---|---|
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Immunocompromised patients with leukemia/lymphoma often have a suboptimal response to vaccination against SARS-CoV-2 and, if infected, can develop a persistent infection.SARS-CoV-2 PCR was performed on nasopharingeal swabs and serum IgG anti-SARS-CoV-2 trimeric spike glycoprotein antibodies were measured during persistence of infection. Treatment with a combination of nirmatrelvir/ritonavir plus sotrovimab led to viral clearance in three patients with leukaemia or lymphoma with persistent SARS-CoV-2 and negative SARS-CoV-2 antibody tests. No standardized treatments for persistent infection with SARS-CoV-2 infection are available. We have reported the viral clearance in two immunocompromised patients treated with antiviral drug nirmatrelvir/ritonavir and monoclonal antibody sotrovimab. We suggest that this strategy should be tested in clinical trials to find the right strategy for a clinical problem with public health implications to SARS-CoV-2 evolution and immune escape in these sub-set of patients. Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Immunocompromised Host; Lymphoma; Persistent Infection; Ritonavir; SARS-CoV-2 | 2023 |
Ergotism caused by concurrent use of ritonavir and ergot alkaloids: a case report.
Topics: Adult; Ergotamine; Ergotism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ischemia; Leg; Lymphoma; Ritonavir; Vasoconstrictor Agents | 2009 |